Guardant Health Inc’s recently made public that its Director Tariq Musa unloaded Company’s shares for reported $11769.0 on Dec 17 ’25. In the deal valued at $101.46 per share,116 shares were sold. As a result of this transaction, Tariq Musa now holds 7,993 shares worth roughly $0.81 million.
Then, Eltoukhy Helmy sold 90,565 shares, generating $9,402,220 in total proceeds. Upon selling the shares at $103.82, the Co-Chief Executive Officer now owns 2,047,143 shares.
Before that, Chudova Darya sold 5,451 shares. Guardant Health Inc shares valued at $567,132 were divested by the Chief Technology Officer at a price of $104.04 per share. As a result of the transaction, Chudova Darya now holds 7,012 shares, worth roughly $0.71 million.
Evercore ISI downgraded its Guardant Health Inc [GH] rating to an In-line from a an Outperform in a research note published recently. Wolfe Research also remained covering GH and has increased its forecast on September 25, 2025 with a “an Outperform” recommendation from previously “Peer perform” rating.
Price Performance Review of GH
On Monday, Guardant Health Inc [NASDAQ:GH] saw its stock jump 0.13% to $101.87. Over the last five days, the stock has lost -1.08%. Guardant Health Inc shares have risen nearly 233.45% since the year began. Nevertheless, the stocks have fallen -0.26% over the past one year. While a 52-week high of $112.43 was reached on 01/05/26, a 52-week low of $31.72 was recorded on 01/05/26.
Levels Of Support And Resistance For GH Stock
The 24-hour chart illustrates a support level at 98.27, which if violated will result in even more drops to 94.67. On the upside, there is a resistance level at 104.51. A further resistance level may holdings at 107.15.
How much short interest is there in Guardant Health Inc?
A steep rise in short interest was recorded in Guardant Health Inc stocks on 2025-12-15, growing by 0.9 million shares to a total of 9.85 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 8.96 million shares. There was a rise of 9.09%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 10, 2025 when Mizuho began covering the stock and recommended ‘”an Outperform”‘ rating along with a $55 price target.
